Singapore, April 15 -- 4D Path, a US-based company dedicated to personalising cancer care through a novel, physics-informed approach to predicting tumor response to therapy, has announced a collaboration with Japan's Daiichi Sankyo to develop next-generation predictive biomarkers in an antibody drug conjugate (ADC) clinical development programme.

ADCs are among the most promising therapeutic classes in oncology, yet there remains a significant unmet need for scalable biomarkers that predict which patients are most likely to benefit from increasingly complex regimens and combination therapies. This collaboration brings together 4D Path's ability to compute biologically grounded, physics-informed treatment predictive biomarkers f...